leisure time -WSS

leisure time

author：comprehensive 2025-09-30 00:49:07 - browse：89728

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Churchill Downs extends trainer Bob Baffert's ban through 2024

entertainment

focus

WSS

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

Medicare drug price lawsuits could be good politics for Biden

FDA sets aggressive timeline for overhauling inspection procedures

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

HPV vaccine, cervical cancer study delivers historic results

focus

leisure time

focus

In age of alternative facts, a scholarly course on calling out crap

Microsoft launches AI tool for clinical documentation through Epic

23andMe had bad news about my health. I wish a person had delivered it

10 states plan to sue EPA over standards for residential wood

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HPV vaccine, cervical cancer study delivers historic results

How one medical school became remarkably diverse

High breast density mammograms need follow

New air purifier tech could be key to improving indoor air quality

CVS is on a mission to consolidate health care. Will it work?

hotspot

Maisha Meds is a PBM, but don't call it that

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Churchill Downs extends trainer Bob Baffert's ban through 2024

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

TikTok, Instagram influencers need more rules for drug ads

FDA sets aggressive timeline for overhauling inspection procedures

hotspot

entertainment

focus

hotspot